Blood Group Genotyping for Sickle Cell and Thalassaemi
The main output of this programme is for blood group genotyping to become embedded into routine practice. Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
Buyer
NHS England, Leeds
Value
£140,671
Published
3 Sept 2025
Closes
5 May 2025
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Other
Category
Services
Contract starts
11 May 2025
Contract ends
31 Mar 2026
CPV classifications
85111810
Blood analysis services
Lots
Lot default Blood Group Genotyping for Sickle Cell and Thalassaemi
£140,671
The main output of this programme is for blood group genotyping to become embedded into routine practice. Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
Delivery: England · United Kingdom, England, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
3 Sept 2025
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.